Crestline Management LP Makes New $901,000 Investment in NewAmsterdam Pharma (NASDAQ:NAMS)

Crestline Management LP bought a new position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 35,068 shares of the company's stock, valued at approximately $901,000.

Other hedge funds also recently made changes to their positions in the company. National Bank of Canada FI purchased a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth about $51,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in NewAmsterdam Pharma in the fourth quarter worth $80,000. Barclays PLC grew its stake in NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company's stock worth $126,000 after purchasing an additional 7,199 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in NewAmsterdam Pharma in the fourth quarter worth $154,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in NewAmsterdam Pharma in the fourth quarter worth $221,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Stock Up 0.3%

NewAmsterdam Pharma stock traded up $0.06 during trading hours on Thursday, hitting $18.81. The stock had a trading volume of 308,192 shares, compared to its average volume of 626,265. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29. The stock has a market capitalization of $2.07 billion, a P/E ratio of -10.02 and a beta of 0.01. The stock's 50-day moving average price is $19.25 and its 200-day moving average price is $21.22.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The business had revenue of $2.98 million during the quarter, compared to the consensus estimate of $1.46 million. On average, research analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insider Transactions at NewAmsterdam Pharma

In other news, Director James N. Topper acquired 1,135 shares of NewAmsterdam Pharma stock in a transaction on Wednesday, March 26th. The shares were acquired at an average price of $22.49 per share, with a total value of $25,526.15. Following the purchase, the director now directly owns 3,013,569 shares in the company, valued at $67,775,166.81. The trade was a 0.04% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now directly owns 15,000 shares in the company, valued at approximately $305,550. The trade was a 90.91% decrease in their position. The disclosure for this sale can be found here. Insiders own 19.50% of the company's stock.

Analyst Ratings Changes

NAMS has been the topic of several recent research reports. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Needham & Company LLC reduced their price target on NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. UBS Group set a $41.00 price target on NewAmsterdam Pharma in a research note on Monday, March 3rd. Finally, Scotiabank increased their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of "Buy" and an average price target of $43.00.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.